Literature DB >> 25971160

Cell line development for biomanufacturing processes: recent advances and an outlook.

Huong Le1, Nandita Vishwanathan, Nitya M Jacob, Mugdha Gadgil, Wei-Shou Hu.   

Abstract

At the core of a biomanufacturing process for recombinant proteins is the production cell line. It influences the productivity and product quality. Its characteristics also dictate process development, as the process is optimized to complement the producing cell to achieve the target productivity and quality. Advances in the past decade, from vector design to cell line screening, have greatly expanded our capability to attain producing cell lines with certain desired traits. Increasing availability of genomic and transcriptomic resources for industrially important cell lines coupled with advances in genome editing technology have opened new avenues for cell line development. These developments are poised to help biosimilar manufacturing, which requires targeting pre-defined product quality attributes, e.g., glycoform, to match the innovator's range. This review summarizes recent advances and discusses future possibilities in this area.

Mesh:

Substances:

Year:  2015        PMID: 25971160     DOI: 10.1007/s10529-015-1843-z

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  5 in total

1.  Monitoring of Microphysiological Systems: Integrating Sensors and Real-Time Data Analysis toward Autonomous Decision-Making.

Authors:  Ashlyn T Young; Kristina R Rivera; Patrick D Erb; Michael A Daniele
Journal:  ACS Sens       Date:  2019-04-19       Impact factor: 7.711

2.  Single Copy Transgene Integration in a Transcriptionally Active Site for Recombinant Protein Synthesis.

Authors:  Sofie A O'Brien; Kyoungho Lee; Hsu-Yuan Fu; Zion Lee; Tung S Le; Christopher S Stach; Meghan G McCann; Alicia Q Zhang; Michael J Smanski; Nikunj V Somia; Wei-Shou Hu
Journal:  Biotechnol J       Date:  2018-07-30       Impact factor: 4.677

3.  Selection of high-producing clones by a relative titer predictive model using image analysis.

Authors:  Weihong Tao; Waqas Ahmed; Meijin Guo; Ali Mohsin; Bing Wu; Rongxiu Li
Journal:  Ann Transl Med       Date:  2021-07

4.  Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies.

Authors:  Parimala Bolisetty; Gabi Tremml; Sen Xu; Anurag Khetan
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

Review 5.  The process defines the product: what really matters in biosimilar design and production?

Authors:  Arnold G Vulto; Orlando A Jaquez
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.